Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 GSK’s Asthma Drug Wins FDA Approval | Contract Pharma

What are you searching for?

Sign in
Trials & Filings

GSK’s Asthma Drug Wins FDA Approval

Nucala shown to reduce frequency of severe asthma attacks

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

GlaxoSmithKline’s Nucala (Mepolizumab) therapy has been approved by the FDA to treat severe asthma attacks in combination with other drugs. Nucala is an injection administered once every four weeks that is approved as an add-on maintenance treatment for patients aged 12 and older.
 
In trials, patients who received Nucala had fewer asthma attacks that required hospitalization or emergency-room visits and reported longer breaks between asthma attacks.
 
The most common reported side effects included redness, swelling and itching in the injection area, back pain and fatigue.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics